Mayo Clinic Consensus Report on Membranous Nephropathy : Proposal for a Novel Classification
Copyright © 2023 International Society of Nephrology and Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights reserved..
Membranous nephropathy (MN) is a pattern of injury caused by autoantibodies binding to specific target antigens, with accumulation of immune complexes along the subepithelial region of glomerular basement membranes. The past 20 years have brought revolutionary advances in the understanding of MN, particularly via the discovery of novel target antigens and their respective autoantibodies. These discoveries have challenged the traditional classification of MN into primary and secondary forms. At least 14 target antigens have been identified, accounting for 80%-90% of cases of MN. Many of the forms of MN associated with these novel MN target antigens have distinctive clinical and pathologic phenotypes. The Mayo Clinic consensus report on MN proposes a 2-step classification of MN. The first step, when possible, is identification of the target antigen, based on a multistep algorithm and using a combination of serology, staining of the kidney biopsy tissue by immunofluorescence or immunohistochemistry, and/or mass spectrometry methodology. The second step is the search for a potential underlying disease or associated condition, which is particularly relevant when knowledge of the target antigen is available to direct it. The meeting acknowledges that the resources and equipment required to perform the proposed testing may not be generally available. However, the meeting consensus was that the time has come to adopt an antigen-based classification of MN because this approach will allow for accurate and specific MN diagnosis, with significant implications for patient management and targeted treatment.
| Errataetall: |
CommentIn: Mayo Clin Proc. 2023 Nov;98(11):1599-1601. - PMID 37804269 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:98 |
|---|---|
| Enthalten in: |
Mayo Clinic proceedings - 98(2023), 11 vom: 06. Nov., Seite 1671-1684 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 06.11.2023 Date Revised 15.11.2023 published: Print-Electronic CommentIn: Mayo Clin Proc. 2023 Nov;98(11):1599-1601. - PMID 37804269 Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.mayocp.2023.08.006 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM362978603 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM362978603 | ||
| 003 | DE-627 | ||
| 005 | 20231226092354.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.mayocp.2023.08.006 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1209.xml |
| 035 | |a (DE-627)NLM362978603 | ||
| 035 | |a (NLM)37804268 | ||
| 035 | |a (PII)S0025-6196(23)00372-5 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Sethi, Sanjeev |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Mayo Clinic Consensus Report on Membranous Nephropathy |b Proposal for a Novel Classification |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 06.11.2023 | ||
| 500 | |a Date Revised 15.11.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentIn: Mayo Clin Proc. 2023 Nov;98(11):1599-1601. - PMID 37804269 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 International Society of Nephrology and Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights reserved. | ||
| 520 | |a Membranous nephropathy (MN) is a pattern of injury caused by autoantibodies binding to specific target antigens, with accumulation of immune complexes along the subepithelial region of glomerular basement membranes. The past 20 years have brought revolutionary advances in the understanding of MN, particularly via the discovery of novel target antigens and their respective autoantibodies. These discoveries have challenged the traditional classification of MN into primary and secondary forms. At least 14 target antigens have been identified, accounting for 80%-90% of cases of MN. Many of the forms of MN associated with these novel MN target antigens have distinctive clinical and pathologic phenotypes. The Mayo Clinic consensus report on MN proposes a 2-step classification of MN. The first step, when possible, is identification of the target antigen, based on a multistep algorithm and using a combination of serology, staining of the kidney biopsy tissue by immunofluorescence or immunohistochemistry, and/or mass spectrometry methodology. The second step is the search for a potential underlying disease or associated condition, which is particularly relevant when knowledge of the target antigen is available to direct it. The meeting acknowledges that the resources and equipment required to perform the proposed testing may not be generally available. However, the meeting consensus was that the time has come to adopt an antigen-based classification of MN because this approach will allow for accurate and specific MN diagnosis, with significant implications for patient management and targeted treatment | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Autoantibodies |2 NLM | |
| 700 | 1 | |a Beck, Laurence H |c Jr |e verfasserin |4 aut | |
| 700 | 1 | |a Glassock, Richard J |e verfasserin |4 aut | |
| 700 | 1 | |a Haas, Mark |e verfasserin |4 aut | |
| 700 | 1 | |a De Vriese, An S |e verfasserin |4 aut | |
| 700 | 1 | |a Caza, Tiffany N |e verfasserin |4 aut | |
| 700 | 1 | |a Hoxha, Elion |e verfasserin |4 aut | |
| 700 | 1 | |a Lambeau, Gérard |e verfasserin |4 aut | |
| 700 | 1 | |a Tomas, Nicola M |e verfasserin |4 aut | |
| 700 | 1 | |a Madden, Benjamin |e verfasserin |4 aut | |
| 700 | 1 | |a Debiec, Hanna |e verfasserin |4 aut | |
| 700 | 1 | |a D'Agati, Vivette D |e verfasserin |4 aut | |
| 700 | 1 | |a Alexander, Mariam P |e verfasserin |4 aut | |
| 700 | 1 | |a Amer, Hatem |e verfasserin |4 aut | |
| 700 | 1 | |a Appel, Gerald B |e verfasserin |4 aut | |
| 700 | 1 | |a Barbour, Sean J |e verfasserin |4 aut | |
| 700 | 1 | |a Caravaca-Fontan, Fernando |e verfasserin |4 aut | |
| 700 | 1 | |a Cattran, Daniel C |e verfasserin |4 aut | |
| 700 | 1 | |a Casal Moura, Marta |e verfasserin |4 aut | |
| 700 | 1 | |a D'Avila, Domingos O |e verfasserin |4 aut | |
| 700 | 1 | |a Eick, Renato G |e verfasserin |4 aut | |
| 700 | 1 | |a Garovic, Vesna D |e verfasserin |4 aut | |
| 700 | 1 | |a Greene, Eddie L |e verfasserin |4 aut | |
| 700 | 1 | |a Herrera Hernandez, Loren P |e verfasserin |4 aut | |
| 700 | 1 | |a Jennette, J Charles |e verfasserin |4 aut | |
| 700 | 1 | |a Lieske, John C |e verfasserin |4 aut | |
| 700 | 1 | |a Markowitz, Glen S |e verfasserin |4 aut | |
| 700 | 1 | |a Nath, Karl A |e verfasserin |4 aut | |
| 700 | 1 | |a Nasr, Samih H |e verfasserin |4 aut | |
| 700 | 1 | |a Nast, Cynthia C |e verfasserin |4 aut | |
| 700 | 1 | |a Pani, Antonello |e verfasserin |4 aut | |
| 700 | 1 | |a Praga, Manuel |e verfasserin |4 aut | |
| 700 | 1 | |a Remuzzi, Giuseppe |e verfasserin |4 aut | |
| 700 | 1 | |a Rennke, Helmut G |e verfasserin |4 aut | |
| 700 | 1 | |a Ruggenenti, Piero |e verfasserin |4 aut | |
| 700 | 1 | |a Roccatello, Dario |e verfasserin |4 aut | |
| 700 | 1 | |a Soler, Maria Jose |e verfasserin |4 aut | |
| 700 | 1 | |a Specks, Ulrich |e verfasserin |4 aut | |
| 700 | 1 | |a Stahl, Rolf A K |e verfasserin |4 aut | |
| 700 | 1 | |a Singh, Raman Deep |e verfasserin |4 aut | |
| 700 | 1 | |a Theis, Jason D |e verfasserin |4 aut | |
| 700 | 1 | |a Velosa, Jorge A |e verfasserin |4 aut | |
| 700 | 1 | |a Wetzels, Jack F M |e verfasserin |4 aut | |
| 700 | 1 | |a Winearls, Christopher G |e verfasserin |4 aut | |
| 700 | 1 | |a Yandian, Federico |e verfasserin |4 aut | |
| 700 | 1 | |a Zand, Ladan |e verfasserin |4 aut | |
| 700 | 1 | |a Ronco, Pierre |e verfasserin |4 aut | |
| 700 | 1 | |a Fervenza, Fernando C |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Mayo Clinic proceedings |d 1964 |g 98(2023), 11 vom: 06. Nov., Seite 1671-1684 |w (DE-627)NLM000074527 |x 1942-5546 |7 nnns |
| 773 | 1 | 8 | |g volume:98 |g year:2023 |g number:11 |g day:06 |g month:11 |g pages:1671-1684 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.mayocp.2023.08.006 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 98 |j 2023 |e 11 |b 06 |c 11 |h 1671-1684 | ||